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Letters to the editor
Prenatal supply of docosahexaenoic acid (DHA): should
we be worried?
Berthold Koletzko*
Department of Paediatrics, Dr. von Hauner Children’s
Hospital, University of Munich, Germany
Sir,
In her insightful and very informative review w6x, Had-
ders-Algra proposes that
1) the supply of docosahexaenoic acid (DHA) without
concomitant arachidonic acid (AA) in early pregnancy
might induce an AA depletion in tissues and thus
should not be recommended, and
2) the evidence for benefits of prenatal DHA is weak.
While the review is extremely thoughtful and reflects
the deep insights of the author into the field, the two
assumptions cited above need be challenged. We fully
agree with Hadders-Algra that AA has its own potent and
biologically important functions, which makes it unwise
to support interventions markedly reducing tissue levels
of AA, but we do not have evidence for any such risk
with a DHA supply in the currently recommended dosage
near 200 mg/day w13, 15x.
Both AA and DHA are formed by endogenous conver-
sion of the precursor essential fatty acids, linoleic acid
and alpha-linolenic acid, respectively w17x. However, AA
is synthesised via a rather short enzyme catalised path-
way of only two desaturation and one elongation steps,
whereas the synthesis of DHA from alpha-linolenic acid
is very long, complex and indirect w17x. Accordingly,
numerous studies using assessment of blood levels or
stable isotope turnover methodology indicate that the
endogenous synthesis of AA is far more effective than
DHA, resulting in a much greater metabolic control and
stability of AA than of DHA levels in human blood and
*Corresponding author:
Berthold Koletzko, MD
Professor of Paediatrics
Department of Paediatrics
Dr. von Hauner Children’s Hospital
Ludwig-Maximilians University of Munich
Lindwurmstr. 4
DE-80337 Muenchen
Germany
Tel.: q49-89-5160-3967
Fax: q49-89-5160-3336
E-mail: Berthold.Koletzko@med.uni-muenchen.de
tissues. For example, infants that either do or do not
receive preformed DHA and AA differ in blood levels of
both fatty acids in the first months of life, whereas at the
end of the first year of life AA but not DHA levels are
equal, indicating a greater degree of endogenous meta-
bolic control of AA than of DHA levels w14x. Moreover,
single nucleotide polymorphisms of the enzymes delta-6
and delta-5 desaturase involved in the synthesis of both
AA and DHA predict about 28% of the variation of AA
levels in plasma phospholipids of free living adults, but
only 1.4–2.9% of the DHA variation w20x. This leads to
the conclusion that humans have a far higher ability for
homeostatic regulation of stable AA than of DHA levels.
This reasoning is further underpinned by the observation
of a rather narrow range of AA levels in human milk
worldwide, in spite of considerable differences in dietary
intake of AA, whereas milk DHA levels vary widely with
diet of the lactating women w1x.
Indeed, the supplementation of women of childbearing
age with a large dose of about 1 g DHA/day in a ran-
domised trial led to a large, 2.6-fold increase of plasma
phospholipid DHA levels over 8 weeks, whereas there
was only a minimal change of AA (y10% of baseline
levels) w4x. Similarly, the daily supplementation of 500 mg
DHA plus 150 mg eicosapentaenoic acid (EPA) to preg-
nant women in a randomised multicentric trial led to sig-
nificantly increased DHA values in placenta as well as
maternal and cord blood lipids, whereas AA levels were
unchanged w12, 20x. The fatty acid composition of infant
brain responded to a postnatal dietary DHA supply (from
breast milk compared to infant formula without DHA or
AA) with an increase of DHA incorporation, whereas brain
AA levels were unaffected by diet w5x. Thus, AA levels in
blood and tissue are relatively stable.
Reassurance on the safety of provision of DHA without
AA is also provided by recent meta-analyses of rando-
mised controlled trials on supplementation of pregnant
women with oils providing either DHA or the combination
of EPA and DHA, but without added AA, which found no
indications of untoward effects of supplementation up to
daily dosages of 1 g DHA, 2.7 g omega 3 LC-PUFA, or
5–6 g fish oil w9, 18, 21x. Cohort studies evaluating habit-
ual intake of fatty fish provides ample DHA and EPA but
little AA throughout pregnancy, also found no adverse
effects but rather benefits on child outcome w8, 19x. Self
selected habitual intake reflects dietary habits and intake
throughout pregnancy.
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The second important question is whether there are
reasonable indications for benefit of a DHA supply to
pregnant women to support the provision of this condi-
tionally essential nutrient. Recent systematic reviews and
meta-analyses of randomised controlled trials (RCT) con-
cluded that the provision of long-chain omega-3 fatty
acids from fish oils (DHA plus EPA) or single cell oils
(DHA) reduce the likelihood of early preterm birth before
34 weeks of gestation by 31% in all pregnancies or by
61% in pregnancies at risk w9, 18x, which translates into
a major benefit with respect to reducing infant morbidity
and mortality.
With respect to reported effects of fish consumption
(providing dietary DHA) or the supplementation of DHA
rich oils on developmental outcome, it is not surprising
that different results have been reported, given the large
differences in interventions and dosages used, different
populations, and huge differences in the choice of out-
comes measured as well as the time points of assess-
ment, and large variation in methodology w2x. However,
while studies have reported either positive or neutral
effects on child developmental outcomes, there are hard-
ly any negative results reported with DHA supply to preg-
nant women, yielding an overall positive balance w2x. For
example, results from a large observational cohort study
assessing fish intake during pregnancy in more than
11,000 women showed that an increased maternal sea-
food consumption was associated with strong beneficial
effects on development of verbal IQ, fine motor function
and social behaviour in the children which were tested
up to the age of 8 years w8x. A dose-response relationship
was found between the amount of seafood consumed
and later verbal IQ development, with close to optimal
outcomes at a fish intake providing approximately
200 mg DHA per day. Similarly, a prospective cohort
study in New England found improved cognitive out-
comes in children, assessed by visual recognition mem-
ory testing, with higher maternal fish consumption during
pregnancy w19x. For each additional weekly fish serving,
the child’s visual recognition memory score was four
points higher. In addition, beneficial effects on cognitive
development of infants and children were found in recent
RCTs on the effects of DHA supplementation during
pregnancy and lactation. The provision of high dose fish
oil to pregnant women in a double blind RCT showed
improved eye-hand coordination in the offspring at the
age of 2.5 years w3x. Another double blind RCT tested
maternal supplementation during pregnancy and lacta-
tion with cod liver oil providing about 1.2 g DHA and
0.8 g EPA, which led to a 4% point advantage in
children’s scores on a standardised Kaufmann ABC intel-
ligence test in children tested at the age of 4 years w7x.
A recent double blind RCT randomised pregnant women
to placebo or supplementation with 300 mg DHA per day,
which improved infant problem-solving at 9 months of
age w10x. While Hadders-Algra is certainly correct in con-
cluding that many more carefully controlled trials should
be performed, and more detailed developmental testing
of children in relation to maternal dietary lipid intake is
highly desirable, the available data support the conclu-
sion that the provision of DHA from adequate sources
during pregnancy without concomitant supplementation
of AA, has no known adverse effects and can provide
relevant benefits.
Based on the available evidence, experts from a large
number of international scientific organisations advise
that pregnant and lactating women should aim at achiev-
ing an average intake of 200 mg DHA/day, and conclud-
ed that no evidence exists that women of child-
bearing age with an adequate dietary intake of linoleic
acid (from vegetable oils) would need an additional diet-
ary intake of AA w13, 15x.
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